Ovarian Cancer: Understanding Risk Factors, Diagnosis, and Advances in Treatment

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2025 | Volume : 14 | Issue : 02 | Page : –
    By

    V. Basil Hans,

  1. Research Professor, Department of Management and Commerce, Srinivas University, Mangalore, Karnataka, India

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_192362’);});Edit Abstract & Keyword

Ovarian cancer is a leading cause of cancer-related mortality among women worldwide, often diagnosed at advanced stages due to its subtle early symptoms. Ovarian cancer develops due to a combination of factors, including genetics, environmental influences, and hormonal changes. This article explores the pathophysiology of ovarian cancer, highlighting the genetic mutations, such as BRCA1 and BRCA2, that contribute to its development. It also discusses current diagnostic methods, including imaging techniques and biomarker identification, which aim to improve early detection and prognosis. Treatment strategies for ovarian cancer include surgery, chemotherapy, targeted therapy, and immunotherapy, with recent advancements in personalized medicine providing more effective and tailored options. Even with advances in treatment, ovarian cancer often comes back, highlighting the ongoing need for further research.. The article concludes by reviewing emerging therapies and ongoing clinical trials, offering hope for improved outcomes and quality of life for patients diagnosed with this aggressive cancer.

Keywords: Aggressive cancer, clinical trials, radiation therapy, follow-up care

[This article belongs to Research and Reviews: Journal of Oncology and Hematology ]

How to cite this article:
V. Basil Hans. Ovarian Cancer: Understanding Risk Factors, Diagnosis, and Advances in Treatment. Research and Reviews: Journal of Oncology and Hematology. 2025; 14(02):-.
How to cite this URL:
V. Basil Hans. Ovarian Cancer: Understanding Risk Factors, Diagnosis, and Advances in Treatment. Research and Reviews: Journal of Oncology and Hematology. 2025; 14(02):-. Available from: https://journals.stmjournals.com/rrjooh/article=2025/view=0


document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_192362’);});Edit

References

  1. Ghoneum A, Afify H, Salih Z, Kelly M, Said N. Role of tumor microenvironment in ovarian cancer pathobiology. J Cancer Metastasis Treat. 2018;4:13. Available from: https://www.ncbi.nlm.nih.gov
  2. Mor G, Alvero A. The duplicitous origin of ovarian cancer. Clin Obstet Gynecol. 2013;56(3):556–64. Available from: https://www.ncbi.nlm.nih.gov
  3. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32. Available from: https://www.ncbi.nlm.nih.gov
  4. Ali AT, Al-ani O, Al-ani F. Epidemiology and risk factors for ovarian cancer. Eur J Gynaecol Oncol. 2023;44(1):1–9. Available from: https://www.ncbi.nlm.nih.gov
  5. Flaum N, Crosbie EJ, Edmondson RJ, Smith MJ, Evans DG. Epithelial ovarian cancer risk: A review of the current genetic landscape. Clin Genet. 2020;97(1):54–64. Available from: https://www.ncbi.nlm.nih.gov
  6. Abdulaziz G, Welc NA, Gąsiorowska E, Nowak-Markwitz E. Assessment of gynecological and lifestyle-related risk factors of ovarian cancer. Prz Menopauzalny. 2021;20(1):32–40. Available from: https://www.ncbi.nlm.nih.gov
  7. Torres A. Dietary and lifestyle modifications in the prevention of epithelial ovarian cancer recurrence. Nutr Cancer. 2017;69(5):814–24.
  8. Mun ST, Jang SH, Ryu A. Early stage ovarian carcinoma with symptoms mimicking tuberculous peritonitis in a postmenopausal woman: A case report. J Ovarian Res. 2018;11(1):51. Available from: https://www.ncbi.nlm.nih.gov
  9. Kozłowski M, Nowak K, Cymbaluk-Płoska A. Long-term follow-up of a female patient treated with Olaparib—Hope for a long life without relapse? Med Sci Monit. 2021;27:e928491. Available from: https://www.ncbi.nlm.nih.gov
  10. Hiss D. Optimizing molecular-targeted therapies in ovarian cancer: The renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. Int J Mol Sci. 2012;13(3):3163–94. Available from: https://www.ncbi.nlm.nih.gov
  11. Pomel C, Jeyarajah A, Oram D, Shepherd J, Milliken D, Dauplat J, Reynolds K. Cytoreductive surgery in ovarian cancer. Eur J Surg Oncol. 2007;33(2):143–9. Available from: https://www.ncbi.nlm.nih.gov
  12. Suh DH, Kim TH, Kim JW, Kim SY, Kim HS, Lee TS, Chung HH, Kim YB, Park NH, Song YS. Improvements to the FIGO staging for ovarian cancer: reconsideration of lymphatic spread and intraoperative tumor rupture. J Gynecol Oncol. 2013;24(3):175–82. Available from: https://www.ncbi.nlm.nih.gov
  13. Trifanescu OG, Mitrica RI, Gales LN, Marinescu SA, Motas N, Trifanescu RA, Rebegea L, Gherghe M, Georgescu DE, Serbanescu GL, Bashar HH, Dragosloveanu S, Cristian DA, Anghel RM. Validation of a new prognostic score in patients with ovarian adenocarcinoma. J Clin Med. 2023;12(4):1234. Available from: https://www.ncbi.nlm.nih.gov
  14. Kurnit KC, Fleming GF, Lengyel E. Updates and new options in advanced epithelial ovarian cancer treatment. Gynecol Oncol. 2021;162(1):3–10. Available from: https://www.ncbi.nlm.nih.gov
  15. Macchia G, Titone F, Restaino S, Arcieri M, Pellecchia G, Andreetta C, et al. Is it time to reassess the role of radiotherapy treatment in ovarian cancer? J Clin Med. 2023;12(2):456. Available from: https://www.ncbi.nlm.nih.gov
  16. Fields EC, McGuire WP, Lin L, Temkin SM. Radiation treatment in women with ovarian cancer: Past, present, and future. Front Oncol. 2017;7:177. Available from: https://www.ncbi.nlm.nih.gov
  17. Smolle E, Taucher V, Pichler M, Petru E, Lax S, Haybaeck J. Targeting signaling pathways in epithelial ovarian cancer. Int J Mol Sci. 2013;14(5):9536–55. Available from: https://www.ncbi.nlm.nih.gov
  18. Campos SM, Ghosh S. A current review of targeted therapeutics for ovarian cancer. J Oncol. 2010;2010:740472. Available from: https://www.ncbi.nlm.nih.gov
  19. Rodriguez GM, Galpin JC, McCloskey CW, Vanderhyden BC. The tumor microenvironment of epithelial ovarian cancer and its influence on response to immunotherapy. Cancers (Basel). 2018;10(8):242. Available from: https://www.ncbi.nlm.nih.gov
  20. Świderska J, Kozłowski M, Kwiatkowski S, Cymbaluk-Płoska A. Immunotherapy of ovarian cancer with particular emphasis on the PD-1/PD-L1 as target points. J Immunol Res. 2021;2021:6613703. Available from: https://www.ncbi.nlm.nih.gov
  21. Martin ML, Halling K, Eek D, Reaney M. “Lower abdominal pains, as if I was being squeezed…in a clamp”: A qualitative analysis of symptoms, patient-perceived side effects, and impacts of ovarian cancer. Eur J Cancer Care (Engl). 2020;29(5):e13280. Available from: https://www.ncbi.nlm.nih.gov
  22. Kahán Z, Szántó I, Dudás R, Kapitány Z, Molnár M, Koncz Z, et al. Breast cancer survivorship programme: Follow-up, rehabilitation, psychosocial oncology care. 1st Central-Eastern European professional consensus statement on breast cancer. Cancer Treat Res Commun. 2022;33:100646. Available from: https://www.ncbi.nlm.nih.gov
  23. Tavares V, Marques IS, Guerra de Melo I, Assis J, Pereira D, Medeiros R. Paradigm shift: A comprehensive review of ovarian cancer management in an era of advancements. Cancers (Basel). 2024;16(1):102. Available from: https://www.ncbi.nlm.nih.gov
  24. Lheureux S, Karakasis K, Kohn EC, Oza AM. Ovarian cancer treatment: The end of empiricism? Cancer. 2015;121(17):3203–11. Available from: https://www.ncbi.nlm.nih.gov
  25. Rath KS, McCann GA, Cohn DE, Rivera BK, Kuppusamy P, Selvendiran K. Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs. J Ovarian Res. 2013;6(1):35. Available from: https://www.ncbi.nlm.nih.gov
  26. Bączyk G, Pleszewa A, Formanowicz D, Kozłowska KA. Quality of life for Polish women with ovarian cancer during first-line chemotherapy. J Clin Med. 2023;12(14):4725. Available from: https://www.ncbi.nlm.nih.gov
  27. Hu S, Baraghoshi D, Chang CP, Rowe K, Snyder J, Deshmukh V, et al. Mental health disorders among ovarian cancer survivors in a population‐based cohort. Psychooncology. 2022;31(2):203–11. Available from: https://www.ncbi.nlm.nih.gov
  28. Hodny E. Increasing awareness and knowledge about ovarian cancer to enhance health outcomes of women. J Womens Health (Larchmt). 2017;26(3):246–50.
Regular Issue Subscription Review Article
Volume 14
Issue 02
Received 29/03/2025
Accepted 04/04/2025
Published 11/06/2025
Publication Time 74 Days
121

[first_name] [last_name]

My IP

PlumX Metrics